131 HARTWELL AVENUE, LEXINGTON, MA
Market cap: $334.5M (2/08/2026)
Price: $5.56
Chief Development Officer Resignation - Stephen G. Machatha Steps Down
Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
Investor Presentation
Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Q3
Q2
Q1
Amended Annual Report
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS
Correspondence
Submission Upload
Confidential Treatment Order